1. Rubiadin has hepatoprotective effects against carbon tetrachloride (CCl 4 )-induced hepatic damage in rats.
2. Rubiadin possesses potent antioxidant property, it can prevent lipid peroxidation induced by FeSO4 and t-butylhydroperoxide (t-BHP) in a dose dependent manner.
3. Rubiadin can decrease bone loss through the inhibition of osteoclast formation,differentiation and bone resorption.
4. Rubiadin exhibits strong antitumor promoting activity at the concentration of 2.0 μg/ml when assayed using the inhibition test of Epstein Barr Virus (EBV) activation on Raji cells.
1. Diosgenin enhances ABCA1-dependent cholesterol efflux and inhibits aortic atherosclerosis progression by suppressing macrophage miR-19b expression.
2. Diosgenin exhibits inhibitory effects on superoxide anion production through the blockade of cAMP, PKA, cPLA2, PAK, Akt and MAPKs signaling pathways, this may explain the clinical implications of Diosgenin in the treatment of inflammation-related disorders.
3. Diosgenin has enough potential to improve the coronary function and interfere the osteochondrogenic transdifferentiation program of aortic VSMC which supports its antivascular calcification potential.
4. Diosgenin suppresses proliferation, inhibits invasion, and suppresses osteoclastogenesis through inhibition of NF-kappaB-regulated gene expression and enhances apoptosis induced by cytokines and chemotherapeutic agents.
5. Diosgenin and L-deprenyl can increase vulnerability of ApoE4 neurons to HIV proteins and opiates, opiate abusers with HIV infection and the ApoE4 allele may be at increased risk of developing dementia, thus they may have therapeutic potential in this population.
1. (-)-Gallocatechin gallate can precipitate cholesterol.
2. (-)-Gallocatechin gallate decreasees osteoclastogenesis at 20 microM.
3. (-)-Gallocatechin gallate inhibits production and extracellular release of maltose binding protein and a periplasmic protein into the culture supernatant.
|CFN99815||Ganoderic acid DM
1. Ganoderic acid DM effectively inhibits cell proliferation and colony formation in MCF-7 human breast cancer cells, which is much stronger than that of MDA-MB-231 breast cancer cells.
2. Ganoderic Acid DM is an antiandrogenic osteoclastogenesis inhibitor.
3. Ganoderic acid DM especially suppresses the expression of c-Fos and nuclear factor of activated T cells c1 (NFATc1), this suppression leads to the inhibition of dendritic cell-specific transmembrane protein (DC-STAMP) expression and reduces osteoclast fusion.
4. Ganoderic acid DM has shown toxicity to both androgen-dependent and independent prostate cancer cells with reduced osteoclastogenesis in late stage metastatic disease, it may an alternative agent for the treatment of advanced prostate cancer.
1. Sarsasapogenin has the effects of being anti-diabetes and improving memory, it can induce cell apoptosis through arrest of cell cycle in G(2)/M phase, it could be used as an anti-cancer drug .
2. Sarsasapogenin can improve memory by elevating the low muscarinic acetylcholine receptor density in brains of memory-deficit rat models.
3. Sarsasapogenin has antidepressant activity, the effect may involve the central monoaminergic neurotransmitter systems.
4. Sarsasapogenin exerts its antitumor activity through both reactive oxygen species (ROS)-mediated mitochondrial dysfunction and endoplasmic reticulum (ER) stress cell death.
5. Sarsasapogenin has protective effects against glutamate-induced neurotoxicity in the cultured cortical neurons in rats.
6. Sarsasapogenin can effectively promote the proliferation,differentiation and mineralization of osteoblasts cultured in vitro, it also can inhibit the generation of osteoclasts from marrow cells.
7. Sarsasapogenin has anti-inflammatory effect.